New infrastructure aims to support clients as they advance from late-stage clinical CMC development through commercialization and post-approval life cycle management.
gChem supplies high-purity DMSO for pharmaceutical innovation—supporting drug discovery, API synthesis, and analytical development. Engineered for safety and performance, our DMSO serves as a versatile excipient or API, playing a vital role in advancing modern medicine.
Abzena is the leading end-to-end bioconjugate (ADC, AOC, & RDC) & complex biologics CDMO + CRO. From discovery through commercial, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development and manufacture of new treatments for patients. Let us help move your program forward faster.
